Drug Monograph

Drug/Drug Class: **Desvenlafaxine Fumarate ER tablet/ SNRI**
Prepared for: MO HealthNet
Prepared by: Xerox Heritage, LLC

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Desvenlafaxine Fumarate ER is available in both a 50 mg and 100 mg extended release tablet. Each extended release tablet contains 50 mg and 100 mg respectively of desvenlafaxine fumarate.
Manufacturer:	Manufactured for: Osmotica Pharmaceutical Corp Marietta, GA 30062 By AAIPharma 1726 North 23rd Street, Wilmington, NC 28405
Indications:	Desvenlfaxine Fumarate ER is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of major depressive disorder (MDD)
Costs:	$4.46 per extended release tablet of Desvenlafaxine Fumarate ER WholesaleAcquisitionCost
Summary of Findings:	The Division recommends adding this drug to the current SNRI and psychotropic polypharmacy clinical edit.
Status Recommendation:	☐ Prior Authorization (PA) Required ☒ Clinical Edit ☐ Fiscal Edit ☐ PDL
Type of PA Criteria:	☐ Increased Risk of ADE ☐ Non-Preferred Agent ☒ Appropriate Indications ☐ No PA Required

Prepared By: Katie Wilbers, PharmD
Date: May 16, 2014